The Dual Effect of Rho-Kinase Inhibition on Trabecular Meshwork Cells Cytoskeleton and Extracellular Matrix in an In Vitro Model of Glaucoma.
3D culture
Matrigel
cytoskeleton
glaucoma
intraocular pressure
outflow
prostaglandin analog
rho-kinase inhibitor
trabecular meshwork
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Feb 2022
15 Feb 2022
Historique:
received:
29
12
2021
revised:
04
02
2022
accepted:
11
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
The trabecular meshwork (TM) is the main site of drainage of the aqueous humor, and its dysfunction leads to intraocular pressure elevation, which is one of the main risk factors of glaucoma. We aimed to compare the effects on cytoskeleton organization and extracellular matrix (ECM) of latanoprost (LT) and a Rho-kinase inhibitor (ROCKi) on a transforming growth factor beta2 (TGF-β2)-induced glaucoma-like model developed from primary culture of human TM cells (pHTMC). The TGF-β2 stimulated pHTMC were grown and incubated with LT or a ROCKi (Y-27632) for 24 h. The expression of alpha-smooth muscle actin (αSMA) and fibronectin (FN), and phosphorylation of the myosin light chain (MLC-P) and Cofilin (Cofilin-P) were evaluated using immunofluorescence and Western blot. The architectural modifications were studied in a Matrigel
Identifiants
pubmed: 35207274
pii: jcm11041001
doi: 10.3390/jcm11041001
pmc: PMC8877133
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int Ophthalmol. 2022 Jan;42(1):281-294
pubmed: 34453229
Exp Eye Res. 2009 Apr;88(4):676-82
pubmed: 19087875
Am J Ophthalmol. 2013 Oct;156(4):731-6
pubmed: 23831221
Ophthalmology. 2018 Nov;125(11):1741-1756
pubmed: 30007591
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
J Glaucoma. 2017 Apr;26(4):390-395
pubmed: 28169917
Oncotarget. 2017 Jun 20;8(25):41749-41763
pubmed: 28445157
Exp Eye Res. 2018 Jun;171:164-173
pubmed: 29526795
Exp Gerontol. 2005 Aug-Sep;40(8-9):745-8
pubmed: 16051457
Mol Vis. 2011;17:1877-90
pubmed: 21850162
JAMA Ophthalmol. 2013 Oct;131(10):1288-95
pubmed: 23787820
Int J Mol Sci. 2021 Nov 19;22(22):
pubmed: 34830390
Graefes Arch Clin Exp Ophthalmol. 2003 Dec;241(12):1037-43
pubmed: 14605906
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):102-9
pubmed: 24359106
J Cardiovasc Pharmacol. 2007 Jul;50(1):17-24
pubmed: 17666911
Toxicol In Vitro. 2017 Jun;41:21-29
pubmed: 28214551
Proteomics. 2010 May;10(9):1886-90
pubmed: 20162561
Clin Ophthalmol. 2014 May 09;8:883-90
pubmed: 24872673
Am J Ophthalmol. 2018 Feb;186:116-127
pubmed: 29199013
Br J Ophthalmol. 2016 Mar;100(3):339-44
pubmed: 26209587
Exp Eye Res. 2020 May;194:108019
pubmed: 32222455
Sci Rep. 2016 Dec 07;6:38319
pubmed: 27924833
Sci Rep. 2021 Jul 27;11(1):15286
pubmed: 34315994
Exp Eye Res. 2017 May;158:23-32
pubmed: 27593914
J Clin Invest. 1989 May;83(5):1661-6
pubmed: 2708527
Exp Eye Res. 2017 May;158:112-123
pubmed: 27443500
Acta Ophthalmol. 2015 Jun;93(4):e254-60
pubmed: 25487877
Sci Rep. 2021 Jul 2;11(1):13762
pubmed: 34215769
Exp Eye Res. 2009 Apr;88(4):769-75
pubmed: 19114037
Am J Ophthalmol. 2008 Jan;145(1):114-9
pubmed: 17988642
Elife. 2021 Mar 30;10:
pubmed: 33783352
Exp Eye Res. 2017 May;158:3-12
pubmed: 27448987
Sci Rep. 2020 Nov 20;10(1):20292
pubmed: 33219246
Am J Physiol Cell Physiol. 2010 Mar;298(3):C749-63
pubmed: 19940066
Adv Drug Deliv Rev. 2014 Dec 15;79-80:3-18
pubmed: 24997339
Exp Eye Res. 2016 Apr;145:393-400
pubmed: 26927931
Exp Cell Res. 2014 Oct 15;328(1):164-171
pubmed: 24992043
Invest Ophthalmol Vis Sci. 2004 Jan;45(1):153-8
pubmed: 14691167
Int J Oncol. 2013 Nov;43(5):1357-67
pubmed: 24042317
Exp Eye Res. 1994 Dec;59(6):723-7
pubmed: 7698265
JAMA Ophthalmol. 2015 Jul;133(7):755-61
pubmed: 25880207
Acta Ophthalmol. 2016 Feb;94(1):e26-34
pubmed: 26338317
Exp Eye Res. 2005 Jan;80(1):121-34
pubmed: 15652533
Arch Ophthalmol. 2002 Oct;120(10):1268-79
pubmed: 12365904
Cytoskeleton (Hoboken). 2010 Sep;67(9):545-54
pubmed: 20803696
Exp Eye Res. 2009 Apr;88(4):648-55
pubmed: 19239914
PLoS One. 2013 Oct 23;8(10):e77232
pubmed: 24194875
Ophthalmology. 2015 Feb;122(2):302-7
pubmed: 25270273
Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1816-25
pubmed: 27082296
Immunobiology. 2016 Feb;221(2):347-56
pubmed: 26466985
Invest Ophthalmol Vis Sci. 2001 Apr;42(5):1029-37
pubmed: 11274082